GNTA
Genenta Science SpA
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
cancer immunotherapy - our gene therapy science to treat cancer we develop a gene transfer strategy into autologous hematopoietic stem/progenitor cells (hspcs) to target interferon-α expression to tumor-infiltrating monocytes/macrophages. an hiv-derived and genetically disabled viral vector - lentivirus - delivers the gene into the hspcs. interferon is a protein usually produced by the body in response to infections that also exhibits a powerful anti-tumor activity. however, the clinical use of interferon as a drug has been limited by its high toxicity. thanks to our innovative therapy, using a combination of transcriptional and microrna-mediated control, tumor-infiltrating monocytes/macrophages become capable to selectively express interferon limited to the tumor area, thus reducing its toxicity. based on these mechanisms, a population of tumor-infiltrating monocytes/macrophages, tie2-expressing monocytes (tems), are armed with a specific drug.
Market Cap: 73.7 Million
Primary Exchange: NASDAQ
Website: genenta.com
Shares Outstanding: 18.2 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 690 trading days
From: 2021-12-27 To: 2024-03-06
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|